BALANCE SHEET COMPONENTS

The following tables summarize the Company's cash equivalents and available-for-sale securities:



	September 28, 2018
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash equivalents
Money market funds	$	44.1	$	—	$	—	$	44.1
Total money market funds	$	44.1	$	—	$	—	$	44.1

Available-for-sale securities
MPTC Series B-1 Bonds ⁽¹⁾	$	25.1	$	—	$	—	$	25.1
MPTC Series B-2 Bonds ⁽²⁾	23.1		—		—		23.1
GPTC securities⁽¹⁾	7.9		—		—		7.9
APTC securities⁽¹⁾	6.4		—		—		6.4
Total available-for-sale securities	$	62.5	$	—	$	—	$	62.5



	September 29, 2017
(In millions)	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Available-for-sale securities
Original CPTC Loans ⁽²⁾	$	47.4	$	—	$	—	$	47.4
DRTC securities⁽²⁾	8.3		—		—		8.3
GPTC securities⁽²⁾	4.4		—		—		4.4
Total available-for-sale securities	$	60.1	$	—	$	—	$	60.1


⁽¹⁾	Included in prepaid and other current assets on the Company's Consolidated Balance Sheets because the Company has the ability and intent to sell this security in the next twelve months.


⁽²⁾	Included in other assets on the Company's Consolidated Balance Sheets because the maturity dates are greater than one year, and the Company does not have the intent and ability to collect or sell all or a portion of its loans or securities in the next twelve months.

See Note 5, "Fair Value" and Note 16, "Proton Solutions Loans and Investment" for more information the Original California Proton Treatment Center, LLC (“Original CPTC”) Loans, Maryland Proton Therapy Center ("MPTC"), Atlanta Proton Therapy Center ("APTC"), Delray Radiation Therapy Center ("DRTC") and Georgia Proton Therapy Center ("GPTC") Securities.

In the fiscal year 2017, the Company's Original CPTC Loans were determined to be other-than-temporarily impaired due to credit losses. As a result of this determination, the investment was written down to its estimated fair value of $47.4 million, resulting in impairment charges of $51.4 million. See Note 16, "Proton Solutions Loans and Investment" for more information on CPTC impairment charges during fiscal year 2018.

The following table provides the Company's unbilled receivables and deferred revenues from contracts with customers:



	September 28,			September 29,
(In millions)	2018			2017
Unbilled receivables - current	$	362.8		$	259.1
Unbilled receivables - long-term ⁽¹⁾	36.3			10.9
Deferred revenues - current	(729.7		)	(755.4		)
Deferred revenues - long-term ⁽²⁾	(38.6		)	$	(7.2	)
Total net unbilled receivables (deferred revenues)	$	(369.2	)	$	(492.6	)


⁽¹⁾	Included in other assets on the Company's Consolidated Balance Sheets.


⁽²⁾	Included in other long-term liabilities on the Company's Consolidated Balance Sheets.

During fiscal year 2018, unbilled receivables net of deferred revenues increased by $123.4 million primarily due to the contractual timing of billings occurring after the revenues were recognized, as well as the timing of milestone payments.

During fiscal year 2018, the Company recognized revenues of $407.0 million which was included in the deferred revenues balance as of September 29, 2017. During fiscal year 2017, the Company recognized revenues of $468.9 million which was included in the deferred revenues balance as of September 30, 2016.

The Company did not record a significant allowance for doubtful accounts on its unbilled receivables during fiscal year 2018. The Company recognized an allowance for doubtful accounts for CPTC of $17.2 million from long-term unbilled receivables during fiscal year 2017.

The following table summarizes the Company's inventories:



	September 28,		September 29,
(In millions)	2018		2017
Raw materials and parts	$	304.1	$	296.5
Work-in-process	50.6		47.7
Finished goods	83.4		73.5
Total inventories	$	438.1	$	417.7

The following table summarizes the Company's prepaid expenses and other current assets:



	September 28,		September 29,
(In millions)	2018		2017
Prepaid income taxes	$	48.1	$	59.9
Available-for-sale securities⁽¹⁾	39.4		—
RPTC senior secured debt ⁽¹⁾	24.9		25.4
Prepaid compensation	14.2		11.6
Advance payments to suppliers	16.6		14.9
Other current receivables	24.1		28.7
Other prepaid expenses	66.0		49.8
Total prepaid expenses and other current assets	$	233.3	$	190.3


⁽¹⁾	See Note 16, "Proton Solutions Loans and Investment" for more information on the Company's available-for-sale securities and the Rinecker Proton Therapy Center ("RPTC").

The following table summarizes the Company's property, plant and equipment, net:



	September 28,			September 29,
(In millions)	2018			2017
Land and land improvements	$	44.2		$	44.2
Buildings and leasehold improvements	227.0			220.4
Machinery and equipment	404.0			375.9
Construction in progress	28.6			14.6
	703.8			655.1
Accumulated depreciation and amortization	(429.2		)	(399.8		)
Total property, plant and equipment, net	$	274.6		$	255.3

The following table summarizes the Company's other assets:



	September 28,		September 29,
(In millions)	2018		2017
Long-term receivables, net	$	115.7	$	114.8
Deferred Compensation Plan ("DCP") assets	75.2		72.7
Long-term available-for-sale securities	23.1		60.1
Investments in privately-held companies	39.4		27.1
Other	39.4		26.1
Total other assets	$	292.8	$	300.8

The following table summarizes the Company's accrued liabilities:



	September 28,		September 29,
(In millions)	2018		2017
Accrued compensation and benefits	$	151.1	$	109.7
DCP liabilities	74.4		70.7
Product warranty	40.9		37.0
Income taxes payable	49.0		38.8
Other	104.3		118.7
Total accrued liabilities	$	419.7	$	374.9

The following table summarizes the Company's other long-term liabilities:



	September 28,		September 29,
(In millions)	2018		2017
Long-term income taxes payable	$	189.1	$	48.6
Long-term deferred revenues	38.6		7.2
Deferred income taxes	31.4		17.1
Other	65.2		54.5
Total other long-term liabilities	$	324.3	$	127.4